A randomized clinical trial to assess the effect of zinc and vitamin D supplementation in addition to hypertonic saline on treatment of acute bronchiolitis.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
13 Jun 2022
Historique:
received: 18 08 2021
accepted: 27 04 2022
entrez: 12 6 2022
pubmed: 13 6 2022
medline: 15 6 2022
Statut: epublish

Résumé

Bronchiolitis, the most common cause of hospitalization in infancy has not yet a definitive treatment. This study was conducted to assess the effect of Zinc and vitamin D on treatment of infants with bronchiolitis. In this double blind, randomized clinical trial, 94 infants aged 2 to 23 months, admitted in Mousavi Hospital in Zanjan, Iran, with the diagnosis of acute bronchiolitis were randomly assigned into 3 groups. The control group was only treated with hypertonic saline. The two case groups received either 100 unit/kg/day of Vitamin D or 20 mg/day of zinc in addition to hypertonic saline. Wheezing, duration of hospital stay, cough, cyanosis, respiratory distress and the respiratory rate in the first, third and seventh day of hospitalization were evaluated. There was no significant difference between groups in terms of age, sex, weight, passive smoking, wheezing, oxygen saturation, cyanosis and type of delivery. On the third day of hospitalization, the respiratory rate/min in the control group, the groups receiving vitamin D and zinc were 45.2 ± 10.7, 37.8 ± 3.9 and 41.1 ± 9.1 respectively and the result of repeated measure analysis didn't show any significant difference between the 3 groups (P = 0.562). Duration of hospitalization in the group receiving Vitamin D or zinc and in controls were 4.2 ± 2.6, 4.4 ± 2.2 and 5.1 ± 2.4 days respectively and this difference was not significant. Zinc receiving patients did not differ from the control group regarding to respiratory rate, cyanosis and wheezing. Vitamin D or zinc administration was not effective in reducing respiratory rate in children with bronchiolitis. Trial registration This project was approved by the Institutional Ethics Committee (IR, ZUMS.REC.1396.50), and registered on IRCT (IRCT20131217015835N7).

Sections du résumé

BACKGROUND BACKGROUND
Bronchiolitis, the most common cause of hospitalization in infancy has not yet a definitive treatment. This study was conducted to assess the effect of Zinc and vitamin D on treatment of infants with bronchiolitis.
METHODS METHODS
In this double blind, randomized clinical trial, 94 infants aged 2 to 23 months, admitted in Mousavi Hospital in Zanjan, Iran, with the diagnosis of acute bronchiolitis were randomly assigned into 3 groups. The control group was only treated with hypertonic saline. The two case groups received either 100 unit/kg/day of Vitamin D or 20 mg/day of zinc in addition to hypertonic saline. Wheezing, duration of hospital stay, cough, cyanosis, respiratory distress and the respiratory rate in the first, third and seventh day of hospitalization were evaluated.
RESULTS RESULTS
There was no significant difference between groups in terms of age, sex, weight, passive smoking, wheezing, oxygen saturation, cyanosis and type of delivery. On the third day of hospitalization, the respiratory rate/min in the control group, the groups receiving vitamin D and zinc were 45.2 ± 10.7, 37.8 ± 3.9 and 41.1 ± 9.1 respectively and the result of repeated measure analysis didn't show any significant difference between the 3 groups (P = 0.562). Duration of hospitalization in the group receiving Vitamin D or zinc and in controls were 4.2 ± 2.6, 4.4 ± 2.2 and 5.1 ± 2.4 days respectively and this difference was not significant. Zinc receiving patients did not differ from the control group regarding to respiratory rate, cyanosis and wheezing.
CONCLUSION CONCLUSIONS
Vitamin D or zinc administration was not effective in reducing respiratory rate in children with bronchiolitis. Trial registration This project was approved by the Institutional Ethics Committee (IR, ZUMS.REC.1396.50), and registered on IRCT (IRCT20131217015835N7).

Identifiants

pubmed: 35692038
doi: 10.1186/s12879-022-07492-2
pii: 10.1186/s12879-022-07492-2
pmc: PMC9190165
doi:

Substances chimiques

Bronchodilator Agents 0
Saline Solution, Hypertonic 0
Vitamin D 1406-16-2
Zinc J41CSQ7QDS

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

538

Informations de copyright

© 2022. The Author(s).

Références

Lancet. 2004 May 22;363(9422):1683-8
pubmed: 15158629
J Infect Dis. 2007 Sep 15;196(6):826-34
pubmed: 17703412
Iran J Med Sci. 2018 Mar;43(2):125-139
pubmed: 29749981
BMJ Nutr Prev Health. 2020 Jun 17;3(1):111-117
pubmed: 33235974
Lancet. 2017 Jan 14;389(10065):211-224
pubmed: 27549684
Iran J Pediatr. 2011 Sep;21(3):409-10
pubmed: 23056823
Jpn J Infect Dis. 2020 Nov 24;73(6):443-446
pubmed: 32611972
Am J Rhinol Allergy. 2010 Jan-Feb;24(1):6-10
pubmed: 20109308
BMJ Open. 2015 Sep 11;5(9):e007828
pubmed: 26362661
Med Hypotheses. 2020 Nov;144:109848
pubmed: 32512490
Clin Nutr. 2013 Apr;32(2):193-9
pubmed: 22981241
Eur J Clin Nutr. 2009 Feb;63(2):297-9
pubmed: 17971825
J Trop Pediatr. 2013 Feb;59(1):29-35
pubmed: 23022743
Allergy. 2019 Jan;74(1):40-52
pubmed: 30276826
Iran J Pediatr. 2011 Jun;21(2):231-4
pubmed: 23056793
Balkan Med J. 2016 Mar;33(2):193-7
pubmed: 27403389
J Pediatr. 2018 Dec;203:416-422.e1
pubmed: 30243543
Indian Pediatr. 2014 Oct;51(10):780-4
pubmed: 25362008
J Nutr. 2008 Dec;138(12):2462-7
pubmed: 19022973
J Pediatric Infect Dis Soc. 2015 Sep;4(3):182-8
pubmed: 26336601
BMC Pediatr. 2021 Apr 30;21(1):211
pubmed: 33931018
Afr Health Sci. 2014 Mar;14(1):136-42
pubmed: 26060470
Nat Immunol. 2005 Oct;6(10):995-1001
pubmed: 16155572
Pediatr Pulmonol. 2009 Oct;44(10):981-8
pubmed: 19746437
BMC Med. 2012 Feb 08;10:14
pubmed: 22316073
BMC Infect Dis. 2015 Oct 28;15:487
pubmed: 26521023
Pediatrics. 2011 Jun;127(6):e1513-20
pubmed: 21555499
Nat Rev Immunol. 2003 Sep;3(9):710-20
pubmed: 12949495
J Trop Pediatr. 2014 Apr;60(2):104-11
pubmed: 24194421

Auteurs

Parisa Khoshnevisasl (P)

Social Determinants of Health Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.

Mansour Sadeghzadeh (M)

Metabolic Disease Research Center, Zanjan University of Medical Sciences, Zanjan, Iran. sadeghzadeh@zums.ac.ir.

Koorosh Kamali (K)

Social Determinants of Health Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.

Armita Ardalani (A)

Department of Pediatrics, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH